Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Heart and Vascular Institute, Cleveland, OH, USA.
School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Curr Cardiol Rep. 2019 Sep 7;21(10):126. doi: 10.1007/s11886-019-1211-z.
Drug-coated balloons (DEB) and drug-eluting stents (DES) emerged as a tool to aid in lowering the rates of neointimal hyperplasia and target lesion restenosis following endovascular peripheral arterial disease (PAD) interventions.
Although the initial trials comparing these devices with non-drug balloons and stents showed favorable results, more recent data raised concerns regarding the mid to long-term safety of these devices. In this review, we will discuss the evolution of endovascular therapy for PAD, with highlights regarding the recent debates on the long-term safety of the drug-coated devices for treatment of PAD.
药物涂层球囊(DEB)和药物洗脱支架(DES)的出现是一种辅助降低血管成形术治疗外周动脉疾病(PAD)后新生内膜过度增生和靶病变再狭窄的工具。
虽然最初比较这些设备与非药物球囊和支架的试验显示了有利的结果,但最近的数据对这些设备的中期至长期安全性提出了担忧。在这篇综述中,我们将讨论 PAD 的血管内治疗的发展,并重点讨论关于药物涂层器械治疗 PAD 的长期安全性的最新争议。